Prevalence of resistance and HIV-1 protease mutation patterns after failures with fosamprenavir-containing regimens

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1758-2652

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Prevalence of resistance and HIV-1 protease mutation patterns after failures with fosamprenavir-containing regimens ; volume:13 ; number:4 ; day:8 ; month:11 ; year:2010 ; pages:1 ; date:12.2010
Journal of the International AIDS Society / International AIDS Society ; 13, Heft 4 (8.11.2010), 1, 12.2010

Creator: Marcelin, AG

Contributor: Charpentier, C.
Ferreira, C.
Wirden, M.
Lemarchand, C.
Descamps, D.
CALVEZ, V.
SpringerLink (Online service)

DOI: 10.1186/1758-2652-13-S4-P136

URN: urn:nbn:de:1111-2016052059105

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:44 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Marcelin, AG
Charpentier, C.
Ferreira, C.
Wirden, M.
Lemarchand, C.
Descamps, D.
CALVEZ, V.
SpringerLink (Online service)

Other Objects (12)

Mutations in the protease gene associated with virological failure to lopinavir-containing regimens in clinical samples

Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children

Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens

Virological and immunological response to three boosted protease inhibitor regimens

Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI

Lipometabolic side-effects of three ritonavir-boosted double protease inhibitor regimens without reverse transcriptase inhibitors

Arbeitspapier | Working paper

Merger failures

Arbeitspapier

Merger failures

Grafik

Photographic failures

Merger failures

Virological failure and predictors in patients with clinical and immunological failures to first-line ARV regimens in Vietnam

Reasons for using and efficacy of raltegravir in salvage regimens without protease inhibitors in clinical practice

Mutations in the protease gene associated with virological failure to lopinavir-containing regimens in clinical samples

Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children

Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens

Virological and immunological response to three boosted protease inhibitor regimens

Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI

Lipometabolic side-effects of three ritonavir-boosted double protease inhibitor regimens without reverse transcriptase inhibitors

Arbeitspapier | Working paper

Merger failures

Arbeitspapier

Merger failures

Grafik

Photographic failures

Merger failures

Virological failure and predictors in patients with clinical and immunological failures to first-line ARV regimens in Vietnam

Reasons for using and efficacy of raltegravir in salvage regimens without protease inhibitors in clinical practice

Mutations in the protease gene associated with virological failure to lopinavir-containing regimens in clinical samples

Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children

Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens

Virological and immunological response to three boosted protease inhibitor regimens

Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI

Lipometabolic side-effects of three ritonavir-boosted double protease inhibitor regimens without reverse transcriptase inhibitors

Arbeitspapier | Working paper

Merger failures

Arbeitspapier

Merger failures

Grafik

Photographic failures

Merger failures

Virological failure and predictors in patients with clinical and immunological failures to first-line ARV regimens in Vietnam

Reasons for using and efficacy of raltegravir in salvage regimens without protease inhibitors in clinical practice

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Prevalence of resistance and HIV-1 protease mutation patterns after failures with fosamprenavir-containing regimens

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Mutations in the protease gene associated with virological failure to lopinavir-containing regimens in clinical samples

Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children

Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens

Virological and immunological response to three boosted protease inhibitor regimens

Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI

Lipometabolic side-effects of three ritonavir-boosted double protease inhibitor regimens without reverse transcriptase inhibitors

Merger failures

Merger failures

Photographic failures

Merger failures

Virological failure and predictors in patients with clinical and immunological failures to first-line ARV regimens in Vietnam

Reasons for using and efficacy of raltegravir in salvage regimens without protease inhibitors in clinical practice

Mutations in the protease gene associated with virological failure to lopinavir-containing regimens in clinical samples

Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children

Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens

Virological and immunological response to three boosted protease inhibitor regimens

Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI

Lipometabolic side-effects of three ritonavir-boosted double protease inhibitor regimens without reverse transcriptase inhibitors

Merger failures

Merger failures

Photographic failures

Merger failures

Virological failure and predictors in patients with clinical and immunological failures to first-line ARV regimens in Vietnam

Reasons for using and efficacy of raltegravir in salvage regimens without protease inhibitors in clinical practice

Mutations in the protease gene associated with virological failure to lopinavir-containing regimens in clinical samples

Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children

Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens

Virological and immunological response to three boosted protease inhibitor regimens

Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI

Lipometabolic side-effects of three ritonavir-boosted double protease inhibitor regimens without reverse transcriptase inhibitors

Merger failures

Merger failures

Photographic failures

Merger failures

Virological failure and predictors in patients with clinical and immunological failures to first-line ARV regimens in Vietnam

Reasons for using and efficacy of raltegravir in salvage regimens without protease inhibitors in clinical practice

Related objects

Reset password